June 27, 2022
In this webinar, Steven C. Katz, M.D., FACS, Chief Medical Officer at TriSalus Life Sciences®️, leads a review of the Pressure-Enabled Regional Immuno-Oncology (PERIO™️-02) clinical trial for adults with intrahepatic cholangiocarcinoma and hepatocellular carcinoma, the most common primary liver tumors. Dr. Katz is joined by Milind Javle, M.D., Professor of GI Medical Oncology at MD Anderson Cancer Center and Rahul Sheth, M.D., Associate Professor in the Department of Interventional Radiology at the MD Anderson Cancer Center.
The PERIO-02 trial is evaluating SD-101, an investigational toll-like receptor 9 (TLR9) agonist, delivered intravascularly by the TriNav®️ Infusion System using the Pressure-Enabled Drug Delivery™️ (PEDD™️) method of administration. The study objective is to understand the ability of this platform to overcome two major challenges of treatment: immune response suppression and ineffective drug delivery.